AKT1 and colorectal carcinoma: AMPK increases the sensitivity of human pancreatic cancer cells to cuproptosis, owing to AMPK‐induced suppression of glycolysis.[58] Similarly, ACOD1 enhances the susceptibility of CRC cells to cuproptosis by inhibiting aerobic glycolysis.[59] Our findings revealed that the AKT1 inhibitor, MK2206, inhibited glycolysis in TNBC cells, thus, the combination of elesclomol with the AKT1 inhibitor has been shown to synergistically reduce cell viability.